Ablation of Cbl-b provides protection against transplanted and spontaneous tumors
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
A significant challenge to efforts aimed at inducing effective antitumor immune responses is that CD8(+) T cells, which play a prominent role in these responses, may be unable to respond to tumors that lack costimulatory signals and that are protected by an immune suppressive environment such as that mediated by TGF-beta produced by tumor cells themselves or by infiltrating Tregs, often resulting in tolerance or anergy of tumor-specific T cells. Here we show that the in vitro activation of Cblb(-/-) CD8(+) T cells does not depend on CD28 costimulation and is resistant to TGF-beta suppression. In vivo studies further demonstrated that Cblb(-/-) mice, but not WT controls, efficiently rejected inoculated E.G7 and EL4 lymphomas that did not express B7 ligands and that introduction of the Cblb(-/-) mutation into tumor-prone ataxia telangiectasia mutated-deficient mice markedly reduced the incidence of spontaneous thymic lymphomas. Immunohistological study showed that E.G7 tumors from Cblb(-/-) mice contained massively infiltrating CD8(+) T cells. Adoptive transfer of purified Cblb(-/-) CD8(+) T cells into E.G7 tumor-bearing mice led to efficient eradication of established tumors. Thus, our data indicate that ablation of Cbl-b can be an efficient strategy for eliciting immune responses against both inoculated and spontaneous tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among these, CBLB has been best studied as an intracellular immune checkpoint that can be targeted in T cells to improve tumor control in mouse models (Chiang et al., 2007; Hinterleitner et al., 2012).”
From Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function (2018) · cites this paper as Chiang et al., 2007
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
T cell receptor antagonist peptides induce positive selection
Hogquist, K. A., Jameson, S. C., Heath, W. R., Howard, J. L., Bevan, M. J., & Carbone, F. R. (1994) · Cell · doi:10.1016/0092-8674(94)90169-4 · Cited by 2,858
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
Groh, V., Wu, J., Yee, C., & Spies, T. (2002) · Nature · doi:10.1038/nature01112 · Cited by 1,592
Atm-Deficient Mice: A Paradigm of Ataxia Telangiectasia
Barlow, C., Hirotsune, S., Paylor, R., Liyanage, M., Eckhaus, M., Collins, F., Shiloh, Y., Crawley, J. N., Ried, T., Tagle, D., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)80086-0 · Cited by 1,458
Progress in human tumour immunology and immunotherapy
Rosenberg, S. A. (2001) · Nature · doi:10.1038/35077246 · Cited by 1,325
Schwartz, R. H. (1992) · Cell · doi:10.1016/s0092-8674(05)80055-8 · Cited by 1,293
Tumor Antigens Recognized by T Lymphocytes
Boon, T., Cerottini, J.-C., Van den Eynde, B., van der Bruggen, P., & Van Pel, A. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.002005 · Cited by 1,221
Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma Cells
Townsend, S. E., & Allison, J. P. (1993) · Science · doi:10.1126/science.7678351 · Cited by 1,136
Introduction of soluble protein into the class I pathway of antigen processing and presentation
Moore, M. W., Carbone, F. R., & Bevan, M. J. (1988) · Cell · doi:10.1016/s0092-8674(88)91043-4 · Cited by 1,092
The Tyrosine Kinase Negative Regulator c-Cbl as a RING-Type, E2-Dependent Ubiquitin-Protein Ligase
Joazeiro, C. A. P., Wing, S. S., Huang, H.-K., Leverson, J. D., Hunter, T., & Liu, Y.-C. (1999) · Science · doi:10.1126/science.286.5438.309 · Cited by 1,034
Chambers, C. A., Kuhns, M. S., Egen, J. G., & Allison, J. P. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.565 · Cited by 998
Research works printed but not linked: 1
- Somasundaram, 2002, Cancer Res., 62, 5267
Cited by
Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function
Shifrut, E., Carnevale, J., Tobin, V., Roth, T. L., Woo, J. M., Bui, C. T., Li, P. J., Diolaiti, M. E., Ashworth, A., & Marson, A. (2018) · Cell · doi:10.1016/j.cell.2018.10.024 · Cited by 573
The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells
Paolino, M., Choidas, A., Wallner, S., Pranjic, B., Uribesalgo, I., Loeser, S., Jamieson, A. M., Langdon, W. Y., Ikeda, F., Fededa, J. P., et al. (2014) · Nature · doi:10.1038/nature12998 · Cited by 456
Lipkowitz, S., & Weissman, A. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3120 · Cited by 415
Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion
Gumber, D., & Wang, L. D. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.103941 · Cited by 396
Pellegrini, M., Calzascia, T., Elford, A. R., Shahinian, A., Lin, A. E., Dissanayake, D., Dhanji, S., Nguyen, L. T., Gronski, M. A., Morre, M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1953 · Cited by 228
Braun, M., Aguilera, A. R., Sundarrajan, A., Corvino, D., Stannard, K., Krumeich, S., Das, I., Lima, L. G., Meza Guzman, L. G., Li, K., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.09.010 · Cited by 171
Shah, N. N., Qin, H., Yates, B., Su, L., Shalabi, H., Raffeld, M., Ahlman, M. A., Stetler-Stevenson, M., Yuan, C., Guo, S., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000219 · Cited by 165
Deletion of Cbl-b inhibits CD8 + T-cell exhaustion and promotes CAR T-cell function
Kumar, J., Kumar, R., Singh, A. K., Tsakem, E. L., Kathania, M., Riese, M. J., Theiss, A. L., Davila, M. L., & Venuprasad, K. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001688 · Cited by 171
The expanding role for small molecules in immuno-oncology
Offringa, R., Kötzner, L., Huck, B. R., & Urbahns, K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00538-9 · Cited by 150
Enhanced Effector Responses in Activated CD8+ T Cells Deficient in Diacylglycerol Kinases
Riese, M. J., Wang, L.-C. S., Moon, E. K., Joshi, R. P., Ranganathan, A., June, C. H., Koretzky, G. A., & Albelda, S. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3874 · Cited by 126
Kim, H. S., Das, A., Gross, C. C., Bryceson, Y. T., & Long, E. O. (2010) · Immunity · doi:10.1016/j.immuni.2010.02.004 · Cited by 124
Naringenin reduces lung metastasis in a breast cancer resection model
Qin, L., Jin, L., Lu, L., Lu, X., Zhang, C., Zhang, F., & Liang, W. P. (2011) · Protein & Cell · doi:10.1007/s13238-011-1056-8 · Cited by 118
Liyasova, M. S., Ma, K., & Lipkowitz, S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2490 · Cited by 99
Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches
Carotta, S. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00152 · Cited by 107
E3 ubiquitin ligase Cbl-b in innate and adaptive immunity
Qingjun, L., Zhou, H., Langdon, W. Y., & Zhang, J. (2014) · Cell Cycle · doi:10.4161/cc.29213 · Cited by 121
Regulation of efferocytosis as a novel cancer therapy
Zhou, Y., Yao, Y., Deng, Y., & Shao, A. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00542-9 · Cited by 100
Burkart, C., Arimoto, K., Tang, T., Cong, X., Xiao, N., Liu, Y., Kotenko, S. V., Ellies, L. G., & Zhang, D. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201864 · Cited by 100
Regulation of immune responses by E3 ubiquitin ligase Cbl-b
Tang, R., Langdon, W. Y., & Zhang, J. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.11.002 · Cited by 107
Essential Role of E3 Ubiquitin Ligase Activity in Cbl-b–Regulated T Cell Functions
Paolino, M., Thien, C. B. F., Gruber, T., Hinterleitner, R., Baier, G., Langdon, W. Y., & Penninger, J. M. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003390 · Cited by 91
Modulation of Immune Cell Functions by the E3 Ligase Cbl-b
Lutz‐Nicoladoni, C., Wolf, D. G. F., & Sopper, S. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00058 · Cited by 104
Stromnes, I. M., Blattman, J. N., Tan, X., Jeevanjee, S., Gu, H., & Greenberg, P. D. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41991 · Cited by 85
Self-citationAlzabin, S., Pyarajan, S., Yee, H. T., Kiefer, F., Suzuki, A., Burakoff, S. J., & Sawasdikosol, S. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0761-0 · Cited by 85
Targeting ubiquitin signaling for cancer immunotherapy
Zhou, X., & Sun, S. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00421-2 · Cited by 100
Gruber, T., Hermann-Kleiter, N., Hinterleitner, R., Fresser, F., Schneider, R., Gastl, G., Penninger, J. M., & Baier, G. (2009) · Science Signaling · doi:10.1126/scisignal.2000046 · Cited by 79
Negative regulation of lymphocyte development and function by the Cbl family of proteins
Huang, F., & Gu, H. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00655.x · Cited by 76
Self-citationMolecular and Cellular Mechanisms of Photocarcinogenesis†
Beissert, S., & Loser, K. (2007) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2007.00231.x · Cited by 80
Breaking Free of Control: How Conventional T Cells Overcome Regulatory T Cell Suppression
Mercadante, E. R., & Lorenz, U. M. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00193 · Cited by 71
From T‐cell activation signals to signaling control of anti‐cancer immunity
Cronin, S. J. F., & Penninger, J. M. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00570.x · Cited by 87
The role of E3 ligases in autoimmunity and the regulation of autoreactive T cells
Lin, A. E., & Mak, T. W. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.10.002 · Cited by 69
Mori, D., Grégoire, C., Voisinne, G., Celis‐Gutierrez, J., Aussel, R., Girard, L., Camus, M., Marcellin, M., Argenty, J., Burlet‐Schiltz, O., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20201011 · Cited by 76
Riese, M. J., Grewal, J., Das, J., Zou, T., Patil, V., Chakraborty, A. K., & Koretzky, G. A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.171884 · Cited by 65
Hinterleitner, R., Gruber, T., Pfeifhofer-Obermair, C., Lutz-Nicoladoni, C., Tzankov, A., Schuster, M., Penninger, J. M., Loibner, H., Lametschwandtner, G., Wolf, D., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044295 · Cited by 59
Targeted Tumor Therapy Remixed—An Update on the Use of Small-Molecule Drugs in Combination Therapies
Gatzka, M. (2018) · Cancers · doi:10.3390/cancers10060155 · Cited by 61
Paolino, M., & Penninger, J. M. (2010) · Seminars in Immunopathology · doi:10.1007/s00281-010-0197-9 · Cited by 66
Turning the Tide Against Regulatory T Cells
Han, S., Toker, A., Liu, Z. Q., & Ohashi, P. S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00279 · Cited by 60
Rausch, L., & Kallies, A. (2025) · Annual Review of Immunology · doi:10.1146/annurev-immunol-082223-044122 · Cited by 70
Naramura, M., Nandwani, N., Gu, H., Band, V., & Band, H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007575107 · Cited by 58
Self-citationNurieva, R., Wang, J., & Sahoo, A. (2013) · Immunotherapy · doi:10.2217/imt.13.33 · Cited by 68
Ubiquitin Ligases in Cancer Immunotherapy – Balancing Antitumor and Autoimmunity
Fujita, Y., Tinoco, R., Li, Y., Senft, D., & Ronai, Z. A. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.02.002 · Cited by 58
Gavali, S., Liu, J., Li, X., & Paolino, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910800 · Cited by 59
Cbl-b and Itch: Key Regulators of Peripheral T-cell Tolerance
Venuprasad, K. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4076 · Cited by 52
Voisinne, G., García‐Blesa, A., Chaoui, K., Fiore, F., Bergot, E., Girard, L., Malissen, M., Burlet‐Schiltz, O., Gonzalez de Peredo, A., Malissen, B., et al. (2016) · Molecular Systems Biology · doi:10.15252/msb.20166837 · Cited by 50
Shamim, M. H., Nanjappa, S. G., Singh, A., Plisch, E. H., LeBlanc, S. E., Walent, J. H., Svaren, J. P., Seroogy, C. M., & Suresh, M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.11.7233 · Cited by 49
Cbl-b mediates TGFβ sensitivity by downregulating inhibitory SMAD7 in primary T cells
Gruber, T., Hinterleitner, R., Hermann-Kleiter, N., Meisel, M., Kleiter, I., Wang, C. M., Viola, A., Pfeifhofer-Obermair, C., & Baier, G. (2013) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjt017 · Cited by 39
Cbl-b Deficiency Mediates Resistance to Programed Death-Ligand 1/Programed Death-1 Regulation
Fujiwara, M., Anstadt, E. J., & Clark, R. B. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00042 · Cited by 42
Laletin, V., Bernard, P.-L., Silva, C. C. D., Guittard, G. C., & Nunès, J. A. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005845 · Cited by 49
Adams, C. O., Housley, W. J., Bhowmick, S., Cone, R. E., Rajan, T. V., Forouhar, F., & Clark, R. B. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001171 · Cited by 37
Sitaram, P., Uyemura, B. S., Malarkannan, S., & Riese, M. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235821 · Cited by 45
Exploiting T cell signaling to optimize engineered T cell therapies
Wang, H., Song, X., Shen, L., Wang, X., & Xu, C. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.10.007 · Cited by 40
Jafari, D., Mousavi, M. J., Shahbaz, S. K., Jafarzadeh, L., Tahmasebi, S., Spoor, J. K. H., & Esmaeilzadeh, A. (2021) · Clinical & Experimental Immunology · doi:10.1111/cei.13560 · Cited by 39
Tsai, Y.-L., Arias-Badia, M., Kadlecek, T. A., Lwin, Y. M., Srinath, A., Shah, N. H., Wang, Z., Barber, D. L., Kuriyan, J., Fong, L. H., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.11.010 · Cited by 34
Regulation of immune system development and function by Cbl‐mediated ubiquitination
Li, X., Gong, L., & Gu, H. (2019) · Immunological Reviews · doi:10.1111/imr.12789 · Cited by 33
Self-citationTsai, Y.-C. (2013) · Journal of Cancer Science & Therapy · doi:10.4172/1948-5956.1000215 · Cited by 31
The adhesion molecule PECAM-1 enhances the TGF-β–mediated inhibition of T cell function
Newman, D. K., Fu, G., Adams, T. L., Cui, W., Arumugam, V., Bluemn, T., & Riese, M. J. (2016) · Science Signaling · doi:10.1126/scisignal.aad1242 · Cited by 32
Releasing the Brake: Targeting Cbl-b to Enhance Lymphocyte Effector Functions
Wallner, S., Gruber, T., Baier, G., & Wolf, D. G. F. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/692639 · Cited by 35
Tumor rejection in Cblb −/− mice depends on IL-9 and Th9 cells
Schanz, O., Cornez, I., Yajnanarayana, S. P., David, F. S., Peer, S., Gruber, T., Krawitz, P. M., Brossart, P., Heine, A., Landsberg, J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002889 · Cited by 33
Absence of Grail promotes CD8+ T cell anti-tumour activity
Haymaker, C., Yang, Y., Wang, J., Zou, Q., Sahoo, A., Alekseev, A., Singh, D., Ritthipichai, K., Hailemichael, Y., Hoang, O. N., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00252-w · Cited by 32
Lutz‐Nicoladoni, C., Wallner, S., Stoitzner, P., Pircher, M., Gruber, T., Wolf, A. M., Gastl, G. A., Penninger, J. M., Baier, G., & Wolf, D. G. F. (2011) · Immunology and Cell Biology · doi:10.1038/icb.2011.11 · Cited by 25
Cblb -deficient T cells are less susceptible to PD-L1-mediated inhibition
Peer, S., Baier, G., & Gruber, T. (2017) · Oncotarget · doi:10.18632/oncotarget.18360 · Cited by 27
Zhou, L., Yang, J., Zhang, K., Wang, T., Jiang, S., & Zhang, X. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01361 · Cited by 24
Li, P., Wang, X., Liu, Z., Liu, H., Xu, T., Wang, H., Gomez, D. R., Nguyen, Q., Wang, L., Teng, Y., et al. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.11.008 · Cited by 22
Singh, T. P., Vieyra-Garcia, P. A., Wagner, K., Penninger, J. M., & Wolf, P. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0858-5 · Cited by 22
Kunii, N., Zhao, Y., Jiang, S., Liu, X., Scholler, J., Balagopalan, L., Samelson, L. E., Milone, M. C., & June, C. H. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.130 · Cited by 22
Mansourabadi, A. H., Khosroshahi, L. M., Noorbakhsh, F., & Amirzargar, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107669 · Cited by 24
Kales, S. C., Ryan, P. E., & Lipkowitz, S. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2241 · Cited by 22
Hoyne, G. F., Flening, E., Yabas, M., Teh, C. E., Altin, J. A., Randall, K. L., Thien, C. B. F., Langdon, W. Y., & Goodnow, C. C. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002296 · Cited by 20
Wesley, E., Xin, G., McAllister, D. M., Malarkannan, S., Newman, D. K., Dwinell, M. B., Cui, W., Johnson, B. D., & Riese, M. J. (2018) · ImmunoHorizons · doi:10.4049/immunohorizons.1700055 · Cited by 23
Discovery, Optimization, and Biological Evaluation of Arylpyridones as Cbl-b Inhibitors
Mfuh, A. M., Boerth, J. A., Bommakanti, G., Chan, C., Chinn, A. J., Code, E. L., Fricke, P. J., Giblin, K. A., Gohlke, A., Hansel, C. S., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02083 · Cited by 21
Goetz, B. T., An, W., Mohapatra, B. C., Zutshi, N., Iseka, F., Storck, M. D., Meza, J. L., Sheinin, Y. M., Band, V., & Band, H. (2016) · Oncotarget · doi:10.18632/oncotarget.9812 · Cited by 16
Han, S., Chung, D. C., Paul, M. S., Liu, Z. Q., Garcia-Batres, C. R., Elford, A. R., Tran, C. W., Chapatte, L., & Ohashi, P. S. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1737368 · Cited by 25
Cbl‐family proteins as regulators of cytoskeleton‐dependent phenomena
Lee, H., & Tsygankov, A. Y. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24412 · Cited by 14
Jiang, W., Wang, D., Wilson, B. A. P., Kang, U., Bokesch, H. R., Smith, E. A., Wamiru, A., Goncharova, E. I., Voeller, D. M., Lipkowitz, S., et al. (2021) · Marine Drugs · doi:10.3390/md19070361 · Cited by 14
Zhou, S.-K., Chen, W., Shi, Z.-D., Wang, S.-P., Li, L., Wen, X., & Wang, Y.-M. (2014) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2014.03.008 · Cited by 14
Ubiquitination of Nonhistone Proteins in Cancer Development and Treatment
Zhang, X., Meng, T., Cui, S., Feng, L., Liu, D., Pang, Q., & Wang, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.621294 · Cited by 16
E3 Ubiquitin Ligases as Immunotherapeutic Target in Atherosclerotic Cardiovascular Disease
Poels, K., Vos, W. G., Lutgens, E., & Seijkens, T. T. P. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00106 · Cited by 13
Han, S., Liu, Z. Q., Chung, D. C., Paul, M. S., Garcia-Batres, C. R., Sayad, A., Elford, A. R., Gold, M. J., Grimshaw, N., & Ohashi, P. S. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0973 · Cited by 16
Targeting the Cbl-b-Notch1 axis as a novel immunotherapeutic strategy to boost CD8+ T-cell responses
Monticone, G., Csibi, F., Leit, S. M., Ciccone, D. N., Champhekar, A. S., Austin, J. E., Ucar-Bilyeu, D. A., Hossain, F., Huang, Z., Ibba, S. V., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.987298 · Cited by 13
Naramura, M., Band, V., & Band, H. (2011) · Communicative & Integrative Biology · doi:10.4161/cib.4.2.14716 · Cited by 11
Simpson-Abelson, M. R., & Bankert, R. B. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.4.477 · Cited by 12
Quan, K. T., Li, D., Wilson, B. A. P., Ranguelova, K., Dalilian, M., Smith, E. A., Wamiru, A., Goncharova, E. I., Grkovic, T., Voeller, D. M., et al. (2022) · Organic Letters · doi:10.1021/acs.orglett.2c03922 · Cited by 10
Casitas b cell lymphoma‑B (Cbl-b): A new therapeutic avenue for small-molecule immunotherapy
Hu, X., Li, E., Zhou, Y., You, Q., & Jiang, Z. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117677 · Cited by 12
Yang, T., Martin, M. L., Nielsen, J. S., Milne, K., Wall, E. M., Lin, W., Watson, P. H., & Nelson, B. H. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0698-3 · Cited by 10
Zha, Y., & Gajewski, T. F. (2007) · Cellular Immunology · doi:10.1016/j.cellimm.2007.07.006 · Cited by 10
Jiang, W., Wang, D., Wilson, B. A. P., Voeller, D. M., Bokesch, H. R., Smith, E. A., Lipkowitz, S., O’Keefe, B. R., & Gustafson, K. R. (2021) · Journal of Natural Products · doi:10.1021/acs.jnatprod.1c00367 · Cited by 10
Zd, S., Xf, L., Hao, L., Zhao, Y., Yx, W., Dong, B.-Z., Wh, C., Zg, Z., Ym, W., Fu, Q., et al. (2014) · PubMed · Cited by 7
Regulation of Lymphatic GM-CSF Expression by the E3 Ubiquitin Ligase Cbl-b
Peer, S., Cappellano, G., Hermann‐Kleiter, N., Albrecht-Schgoer, K., Hinterleitner, R., Baier, G., & Gruber, T. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02311 · Cited by 7
Zhang, Y., Guan, X., Chai, Y., Lu, T., An, N., Lin, X., & Liao, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117488 · Cited by 6
Ubiquitin Signaling in the Immune System
Jin, L. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-981-97-7288-9_8 · Cited by 6
Cbl-b inhibitor NX-1607 activates MAPK/ERK signaling pathway and enhances T-cell activation
Zhu, W., Lu, S., Jia, L., Liu, B., Song, S., Bao, X., Yu, T. Y., Zhang, Y., Miao, Z., & He, J. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011180 · Cited by 10
Engineering effective T-cell based antitumor immunity
Gruber, T., Hinterleitner, R., Pfeifhofer‐Obermair, C., Wolf, D. G. F., & Baier, G. (2013) · OncoImmunology · doi:10.4161/onci.22893 · Cited by 6
Singh, N., Huang, L., & Qin, H. (2009) · European Journal of Immunology · doi:10.1002/eji.200939736 · Cited by 6
Immune Regulation by Ubiquitin Tagging as Checkpoint Code
Zeng, P., Ma, J., Yang, R., & Liu, Y. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_64 · Cited by 7
In Vitro Ubiquitination Platform Identifies Methyl Ellipticiniums as Ubiquitin Ligase Inhibitors
Wilson, B. A. P., Voeller, D. M., Smith, E. A., Wamiru, A., Goncharova, E. I., Liu, G., Lipkowitz, S., & O’Keefe, B. R. (2021) · SLAS DISCOVERY · doi:10.1177/24725552211000675 · Cited by 7
Li, P., Liu, H., Zhang, Z., Lv, X., Chang, Y., Wang, H., Ma, J., Ma, Z., Qu, X., & Teng, Y.-E. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.02.31 · Cited by 4
Nath, P. R., & Isakov, N. (2024) · Life · doi:10.3390/life14121592 · Cited by 4
Cbl-b: Roles in T Cell Tolerance, Proallergic T Cell Development, and Cancer Immunity
Trial, J., Potempa, L. A., & Entman, M. L. (2014) · Inflammation and Cell Signaling · doi:10.14800/ics.146 · Cited by 5
Song, J., Anderson, W., Hu, A. K., Obata‐Ninomiya, K., Ziegler, S. F., Rawlings, D. J., & Buckner, J. H. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2200219 · Cited by 2
CBL-B – An upcoming immune-oncology target
Fusco, R., Saedi, Z., Capriello, I., Lubskyy, A., & Dömling, A. S. S. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2412567 · Cited by 2
Research Highlights: Highlights from the latest Articles in Immunomodulation
Cocco, C., & Airoldi, I. (2012) · Immunotherapy · doi:10.2217/imt.12.56 · Cited by 2
Lu, S., Zhu, W.-T., Song, S.-S., Bao, X., Yu, T. Y., Zhang, Y., Miao, Z., & He, J. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.112051 · Cited by 2
Metadata
- Authors
- Chiang, J. Y., Jang, I. K., Hodes, R., & Gu, H.
- Affiliations
- National Institutes of Health (US)
- Columbia University (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2007-04-02
- Volume
- 117
- Issue
- 4
- Pages
- 1029-1036
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1810570
- OpenAlex
- W1855158451
- Cited by
- 124
- References
- 32
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 6 · 2023: 3 · 2022: 6 · 2021: 10 · 2020: 6 · 2019: 5 · 2018: 8 · 2017: 7 · 2016: 6 · 2015: 2 · 2014: 6 · 2013: 8 · 2012: 7
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- The Journal of Immunology
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- Cbl-b, CD8+ T cells, antitumor immunity, CD28 costimulation, TGF-beta, regulatory T cells, tumor rejection, EL4 lymphoma, ATM kinase, adoptive T cell therapy, tumor immunosuppression, B7 ligands
- MeSH terms
- Animals, Lymphoma, Mice, Inbred C57BL, Neoplasm Transplantation, CD4-Positive T-Lymphocytes, Mice, Knockout, CD8-Positive T-Lymphocytes, Adaptor Proteins, Signal Transducing, Proto-Oncogene Proteins c-cbl, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.